BALLIET JENNIFER 4
4 · NEOGENOMICS INC · Filed Dec 11, 2020
Insider Transaction Report
Form 4
BALLIET JENNIFER
Vice President of HR
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-12-11−15,000→ 33,334 totalExercise: $8.03Exp: 2023-02-26→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2020-12-11$8.03/sh+15,000$120,450→ 39,980 total - Sale
Common Stock
2020-12-11$49.99/sh−15,000$749,850→ 24,980 total
Holdings
- 7,000
Stock Option (Right to Buy)
Exercise: $7.52Exp: 2022-04-28→ Common Stock (7,000 underlying) - 15,006
Stock Option (Right to Buy)
Exercise: $28.33Exp: 2027-03-02→ Common Stock (15,006 underlying) - 17,496
Stock Option (Right to Buy)
Exercise: $19.60Exp: 2024-03-01→ Common Stock (17,496 underlying)
Footnotes (4)
- [F1]On April 28, 2017, Ms. Balliet was granted 60,000 stock options. These options vested ratably over the first three anniversaries of the grant date.
- [F2]On February 26, 2018, Ms. Balliet was granted 72,500 stock options. These options vest ratably over the first three anniversary dates of the grant date.
- [F3]On March 1, 2019, Ms. Balliet was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F4]On March 2, 2020, Ms. Balliet was granted 15,006 stock options. These options vest ratably over the first four anniversary dates of the grant date.